Company news
Atyr Pharma, Inc. (NASDAQ:ATYR) news
Atyr Pharma, Inc. news releases on 6ix. Latest, May 12, 2020: aTyr Pharma Announces First Quarter 2020 Results and Provides Corporate Update on ATYR1923…
Press releases — page 4
aTyr Pharma Announces First Quarter 2020 Results and Provides Corporate Update on ATYR1923 Clinical Trials in Pulmonary Sarcoidosis and COVID-19
May 11, 2020
aTyr Pharma Announces Publication of Two Abstracts in American Journal of Respiratory and Critical Care Medicine
May 4, 2020
aTyr Pharma Announces Phase 2 Study of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications Following FDA Acceptance of IND Application
April 20, 2020
aTyr Pharma Announces Fourth Quarter and Full Year 2019 Results and Provides Corporate Update
March 25, 2020
aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Announce Government Grant to Fund Bispecific Antibody Development Platform
March 23, 2020
aTyr Pharma to Announce Fourth Quarter and Full Year End 2019 Financial Results on March 26th
March 18, 2020
Leading Cancer Researcher Dr. Arthur M. Mercurio Joins aTyr as Scientific Advisor
March 16, 2020
aTyr Pharma Announces Exercise and Closing of Over-Allotment Option in Public Offering
March 9, 2020
aTyr Pharma Announces Publication in the Journal Cellular and Molecular Immunology
February 26, 2020
aTyr Pharma Announces Pricing of $18 million Underwritten Public Offering
February 5, 2020
aTyr Pharma Announces Collaboration with Kyorin Pharmaceutical Co., Ltd. for the Development and Commercialization of ATYR1923 in Japan
January 5, 2020
aTyr Pharma Announces Positive Interim Safety Results from Ongoing Phase 1b/2a Clinical Trial of ATYR1923
December 11, 2019
aTyr Pharma Announces Third Quarter 2019 Results and Provides Corporate Update
November 13, 2019
aTyr Pharma to Announce Third Quarter Results on November 14th
November 6, 2019
aTyr Pharma Announces Research Collaboration with Boston Children’s Hospital
October 21, 2019